Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.46 |
| ▸ | HTR2B | P41595 | 9/20 | 0.46 |
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | LATS1 | O95835 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14442453 | 1.00 | HTR2C (0.46) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL5630306 | 0.88 | HTR2C (0.44) | HTR2CHTR2BHTR2ALATS1DPP4 | |
| SCHEMBL5630299 | 0.88 | HTR2C (0.44) | HTR2CHTR2BHTR2ALATS1DPP4 | |
| SCHEMBL5633015 | 0.88 | HTR2C (0.44) | HTR2CHTR2BHTR2ALATS1DPP4 | |
| SCHEMBL5305264 | 0.88 | HTR2C (0.42) | HTR2CHTR2BHTR2ALATS1CYP1A2 | |
| Hydrochloric Acid SCHEMBL5631402 | 0.86 | HTR2C (0.44) | HTR2CHTR2BHTR2ALATS1DPP4 | |
| Hydrochloric Acid SCHEMBL5633730 | 0.86 | HTR2C (0.44) | HTR2CHTR2BHTR2ALATS1DPP4 | |
| Hydrochloric Acid SCHEMBL5631397 | 0.86 | HTR2C (0.44) | HTR2CHTR2BHTR2ALATS1DPP4 | |
| SCHEMBL5631228 | 0.86 | HTR2C (0.52) | HTR2CHTR2BHTR2AHTR6 | |
| SCHEMBL5632309 | 0.86 | HTR2C (0.52) | HTR2CHTR2BHTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 4/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.